FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2247689163> ?p ?o ?g. }

• W2247689163 endingPage "51" @default.
• W2247689163 startingPage "1845" @default.
• W2247689163 abstract "Tumor necrosis factor-α is a key mediator in the pathogenesis of psoriasis. Infliximab is a monoclonal antibody that specifically binds to tumor necrosis factor-α. The purpose of this study was to validate the efficacy and safety of 5 mg/kg infliximab therapy in Chinese patients with moderate to severe plaque psoriasis.In this multicenter, double-blind, placebo-controlled trial, 129 patients with moderate-to-severe psoriasis were randomized to the induction therapy (weeks 0, 2 and 6) with infliximab 5 mg/kg (n = 84) or placebo (n = 45), followed with infliximab 5 mg/kg scheduled at week 14 and week 22 in the infliximab group, and infliximab 5 mg/kg scheduled at weeks 10, 12 and 16 in the placebo group. The primary end point was the proportion of patients who achieved at least 75% improvement in Psoriasis Area and Severity Index (PASI 75 response rate) from baseline at week 10.At week 10, 81.0% of patients treated with infliximab (5 mg/kg) achieved a 75% or greater improvement compared with 2.2% of patients treated with placebo (P < 0.001). A significant improvement in PASI, Physician's Global Assessment (PGA) and Dermatology Life Quality Index (DLQI), was seen from week 6 through week 14 in the infliximab group compared with the placebo group. Through week 22, PASI, PGA, DLQI were well maintained. The incidence of adverse events for the infliximab treatment group was slightly higher in comparison to the placebo treatment group during the first 10 weeks without statistical significance. However, there were 3 cases of tuberculosis that developed during the 26 weeks treatment with infliximal.Infliximab treatment was effective as induction and maintenance treatments for Chinese patients with moderate to severe plaque psoriasis. Most drug-induced adverse events were mild to moderate, and well tolerated. Screening for tuberculosis is essential and prophylactic treatment should be given if necessary." @default.
• W2247689163 created "2016-06-24" @default.
• W2247689163 creator A5004491361 @default.
• W2247689163 creator A5025832492 @default.
• W2247689163 creator A5027099198 @default.
• W2247689163 creator A5027876738 @default.
• W2247689163 creator A5030552469 @default.
• W2247689163 creator A5031876159 @default.
• W2247689163 creator A5034199802 @default.
• W2247689163 creator A5047013876 @default.
• W2247689163 creator A5052034885 @default.
• W2247689163 creator A5060459013 @default.
• W2247689163 creator A5064315255 @default.
• W2247689163 creator A5072924983 @default.
• W2247689163 creator A5081084797 @default.
• W2247689163 creator A5089555790 @default.
• W2247689163 date "2012-06-01" @default.
• W2247689163 modified "2023-10-16" @default.
• W2247689163 title "Infliximab monotherapy for Chinese patients with moderate to severe plaque psoriasis: a randomized, double-blind, placebo-controlled multicenter trial." @default.
• W2247689163 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22884040" @default.
• W2247689163 hasPublicationYear "2012" @default.
• W2247689163 type Work @default.
• W2247689163 sameAs 2247689163 @default.
• W2247689163 citedByCount "21" @default.
• W2247689163 countsByYear W22476891632012 @default.
• W2247689163 countsByYear W22476891632013 @default.
• W2247689163 countsByYear W22476891632014 @default.
• W2247689163 countsByYear W22476891632015 @default.
• W2247689163 countsByYear W22476891632016 @default.
• W2247689163 countsByYear W22476891632017 @default.
• W2247689163 countsByYear W22476891632018 @default.
• W2247689163 countsByYear W22476891632019 @default.
• W2247689163 countsByYear W22476891632020 @default.
• W2247689163 countsByYear W22476891632021 @default.
• W2247689163 countsByYear W22476891632022 @default.
• W2247689163 countsByYear W22476891632023 @default.
• W2247689163 crossrefType "journal-article" @default.
• W2247689163 hasAuthorship W2247689163A5004491361 @default.
• W2247689163 hasAuthorship W2247689163A5025832492 @default.
• W2247689163 hasAuthorship W2247689163A5027099198 @default.
• W2247689163 hasAuthorship W2247689163A5027876738 @default.
• W2247689163 hasAuthorship W2247689163A5030552469 @default.
• W2247689163 hasAuthorship W2247689163A5031876159 @default.
• W2247689163 hasAuthorship W2247689163A5034199802 @default.
• W2247689163 hasAuthorship W2247689163A5047013876 @default.
• W2247689163 hasAuthorship W2247689163A5052034885 @default.
• W2247689163 hasAuthorship W2247689163A5060459013 @default.
• W2247689163 hasAuthorship W2247689163A5064315255 @default.
• W2247689163 hasAuthorship W2247689163A5072924983 @default.
• W2247689163 hasAuthorship W2247689163A5081084797 @default.
• W2247689163 hasAuthorship W2247689163A5089555790 @default.
• W2247689163 hasConcept C126322002 @default.
• W2247689163 hasConcept C141071460 @default.
• W2247689163 hasConcept C142724271 @default.
• W2247689163 hasConcept C168563851 @default.
• W2247689163 hasConcept C17991360 @default.
• W2247689163 hasConcept C197934379 @default.
• W2247689163 hasConcept C203014093 @default.
• W2247689163 hasConcept C204787440 @default.
• W2247689163 hasConcept C27081682 @default.
• W2247689163 hasConcept C2776173921 @default.
• W2247689163 hasConcept C2777011040 @default.
• W2247689163 hasConcept C2777138892 @default.
• W2247689163 hasConcept C2780564577 @default.
• W2247689163 hasConcept C71924100 @default.
• W2247689163 hasConcept C90924648 @default.
• W2247689163 hasConceptScore W2247689163C126322002 @default.
• W2247689163 hasConceptScore W2247689163C141071460 @default.
• W2247689163 hasConceptScore W2247689163C142724271 @default.
• W2247689163 hasConceptScore W2247689163C168563851 @default.
• W2247689163 hasConceptScore W2247689163C17991360 @default.
• W2247689163 hasConceptScore W2247689163C197934379 @default.
• W2247689163 hasConceptScore W2247689163C203014093 @default.
• W2247689163 hasConceptScore W2247689163C204787440 @default.
• W2247689163 hasConceptScore W2247689163C27081682 @default.
• W2247689163 hasConceptScore W2247689163C2776173921 @default.
• W2247689163 hasConceptScore W2247689163C2777011040 @default.
• W2247689163 hasConceptScore W2247689163C2777138892 @default.
• W2247689163 hasConceptScore W2247689163C2780564577 @default.
• W2247689163 hasConceptScore W2247689163C71924100 @default.
• W2247689163 hasConceptScore W2247689163C90924648 @default.
• W2247689163 hasIssue "11" @default.
• W2247689163 hasLocation W22476891631 @default.
• W2247689163 hasOpenAccess W2247689163 @default.
• W2247689163 hasPrimaryLocation W22476891631 @default.
• W2247689163 hasRelatedWork W1549133529 @default.
• W2247689163 hasRelatedWork W1580608335 @default.
• W2247689163 hasRelatedWork W1925087877 @default.
• W2247689163 hasRelatedWork W1976437285 @default.
• W2247689163 hasRelatedWork W2060546762 @default.
• W2247689163 hasRelatedWork W2127833079 @default.
• W2247689163 hasRelatedWork W2170270641 @default.
• W2247689163 hasRelatedWork W2247689163 @default.
• W2247689163 hasRelatedWork W2282346074 @default.
• W2247689163 hasRelatedWork W2400007513 @default.
• W2247689163 hasVolume "125" @default.
• W2247689163 isParatext "false" @default.
• W2247689163 isRetracted "false" @default.

• next